RE: Unmet Needs14 Jul 2025 07:08
Wakey wakey a kill news to rise n shine too
Solvonis Chair Dennis Purcell to speak at Lucid Capital Markets biotech leadership event.
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders is pleased to announce that its Chairman, Dennis Purcell, will participate in an exclusive investor event hosted by Lucid Capital Markets on Thursday, 17 July 2025 at 2:00pm ET.
The event, moderated by Elemér Piros, PhD, Managing Director and Senior Biotech Analyst at Lucid Capital Markets, features a panel discussion with three of the most influential figures in global biopharma: Dennis Purcell (Chair, Solvonis; Founder, Aisling Capital), Stelios Papadopoulos (Chair, Exelixis), and Jeremy Levin (Chair and CEO, Ovid Therapeutics).
The session will explore leadership, innovation, and strategic capital deployment across the biotechnology sector.